PARSIPPANY, N.J. / Dec 11, 2025 / Business Wire / The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the... Read More

PARSIPPANY, N.J. / Dec 05, 2025 / Business Wire / Zoetis Inc. today announced that Health Canada has approved Portela ™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a nine-month field trial in... Read More

Underscores Proven Innovation Model, Robust and Diversified Pipeline with 12 Potential Blockbuster 1 Candidates, and Unmatched Scale and Capabilities Animal Health Leader Positioned to Deliver Sustained Revenue Growth, Profitability and Shareholder Value PARSIPPANY, N.J. / Dec 02, 2025 / Business Wire / Zoetis Inc . (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET... Read More

PARSIPPANY, N.J. / Nov 26, 2025 / Business Wire / Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia ® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor (NGF),... Read More

PARSIPPANY, N.J. / Nov 20, 2025 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. Investors and other interested parties can access a live... Read More

PARSIPPANY, N.J. / Nov 19, 2025 / Business Wire / Zoetis Inc . (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Executive Vice President and Chief Financial Officer; Rob Polzer, Ph.D., Executive Vice President and President of Research and Development; and Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic), Senior... Read More

Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025 Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025 Revises Full... Read More

Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation PARSIPPANY, N.J. / Nov 03, 2025 / Business Wire / Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the... Read More

PARSIPPANY, N.J. / Oct 29, 2025 / Business Wire / Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela ® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing interval approved for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single... Read More

Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board PARSIPPANY, N.J. / Oct 28, 2025 / Business Wire / Zoetis Inc . (NYSE: ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial... Read More

First long-acting canine anti-nerve growth factor monoclonal antibody therapy administered once every three months Approval marks major milestone in the company’s continued innovation for canine OA pain PARSIPPANY, N.J. / Oct 15, 2025 / Business Wire / Zoetis Inc. today announced that Health Canada has approved Lenivia ® (izenivetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in dogs. Built on... Read More

PARSIPPANY, N.J. / Oct 10, 2025 / Business Wire / Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Lenivia ® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Based on the CVMP’s positive opinion, the European Commission is... Read More

PARSIPPANY, N.J. / Oct 09, 2025 / Business Wire / The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Company’s common stock as of the close of business on Friday, October 31, 2025. About Zoetis As the world’s leading animal health company, Zoetis is driven by a... Read More

With new label, Dectomax ® -CA1 Injectable is the first and only parasite control product with conditional approval to help control economically devastating pest Cochliomyia hominivorax (New World screwworm) PARSIPPANY, N.J. / Sep 30, 2025 / Business Wire / Zoetis Inc. today announced that Dectomax ® -CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug... Read More

PARSIPPANY, N.J. / Sep 23, 2025 / Business Wire / Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the... Read More

PARSIPPANY, N.J. / Sep 12, 2025 / Business Wire / Zoetis Inc . today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Portela ® (relfovetmab), a new monoclonal antibody (mAb) therapy intended for the alleviation of pain associated with osteoarthritis (OA) in cats. Portela Will Be... Read More

PARSIPPANY, N.J. / Aug 27, 2025 / Business Wire / Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8 at 1:05 p.m. ET. Investors and other interested parties can access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay will also be... Read More

PARSIPPANY, N.J. / Aug 11, 2025 / Business Wire / Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billion aggregate principal amount of 5.000% senior notes due 2035, in an underwritten public offering. Zoetis intends to use the net proceeds to repay the principal of (i) its 4.500%... Read More

Reports Revenue of $2.5 Billion, Growing 4%, and Net Income of $718 Million, or $1.61 per Diluted Share, Increasing 15% and 18%, Respectively, on a Reported Basis for Second Quarter 2025 Delivers 8% Organic Operational Growth in Revenue and 10% Organic Operational Growth in Adjusted Net Income for Second Quarter 2025 Reports Adjusted Net Income of $783 Million, or Adjusted Diluted EPS of $1.76, for Second Quarter 2025 Raises... Read More

PARSIPPANY, N.J. / Jul 01, 2025 / Business Wire / Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the... Read More

Increased colleague-reported volunteer hours by 23%, making a difference for animals, those who care for them, and communities Zoetis Foundation dispersed $11.3 million in grants, including funding for nearly 500 veterinary student scholarships Launched strategic partnerships to address sustainability needs for dairy and beef producers Responded to avian influenza challenges with science-driven solutions Sourced 80.6% of... Read More

Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board PARSIPPANY, N.J. / May 22, 2025 / Business Wire / Zoetis Inc . (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company’s annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary... Read More

PARSIPPANY, N.J. / May 21, 2025 / Business Wire / The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will be paid on Wednesday, September 3, 2025, to all holders of record of the Company’s common stock as of the close of business on Friday, July 18, 2025. About Zoetis As the world’s leading animal health company, Zoetis is driven by a... Read More

PARSIPPANY, N.J. / May 15, 2025 / Business Wire / Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. BNP Paribas Animal Health Day on May 22, 2025 at 1:00 p.m. ET Stifel 2025 Jaws and Paws Conference on May 29, 2025 at 9:10 a.m. ET William Blair 45 th Annual Growth Stock Conference on June 3, 2025 at 10:40 a.m. CT Investors and other... Read More

Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quarter 2025 Delivers 9% Organic Operational Growth in Revenue and 6% Organic Operational Growth in Adjusted Net Income for First Quarter 2025 Reports Adjusted Net Income of $662 Million, or Adjusted Diluted EPS of $1.48, for First Quarter 2025 Updates Full... Read More

PARSIPPANY, N.J. / Mar 27, 2025 / Business Wire / Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live... Read More

PARSIPPANY, N.J. / Feb 20, 2025 / Business Wire / Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. Bank of America Securities 2025 Animal Health Summit on Thursday, February 27, 2025 at 1:20 p.m. ET. Barclays Global Healthcare Conference on Tuesday, March 11, 2025 at 10:30 a.m. ET. Investors and other interested parties can access live audio... Read More

PARSIPPANY, N.J. / Feb 14, 2025 / Business Wire / Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonable expectation of efficacy... Read More

Reports Revenue of $2.3 Billion, Growing 5%, and Net Income of $581 Million, or $1.29 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis for Fourth Quarter 2024 Delivers 6% Operational Growth in Revenue and 9% Operational Growth in Adjusted Net Income for Fourth Quarter 2024 Delivers 9% Organic Operational Growth in Revenue for Fourth Quarter 2024 After Accounting for the Divestiture of the... Read More

PARSIPPANY, N.J. / Feb 06, 2025 / Business Wire / The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the second quarter of 2025. The dividend will be paid on Tuesday, June 3, 2025, to all holders of record of the Company’s common stock as of the close of business on Monday, April 21, 2025. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular... Read More

Zoetis Plans to Immediately Implement Updated Label Based on U.S. Post-Approval Experience with Librela Company Remains Confident in the Safety and Effectiveness of Librela and Reaffirms Its Commitment to Supporting Veterinarians and Pet Owners in Helping Dogs with OA Live with Less Pain and Greater Mobility More Than One Million Dogs in the U.S. Have Been Treated with Librela Since Its Launch in the U.S. in October 2023... Read More

PARSIPPANY, N.J. / Dec 12, 2024 / Business Wire / The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% from the quarterly dividend rate paid in 2024. The dividend will be paid on Tuesday, March 4, 2025, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 21, 2025. “Zoetis’ performance... Read More

PARSIPPANY, N.J. / Nov 19, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 11:30 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the session... Read More

New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations PARSIPPANY, N. J. / Nov 11, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all... Read More

PARSIPPANY, N.J. / Nov 07, 2024 / Business Wire / Zoetis Inc . (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 3:00 p.m. GMT. Investors and other interested parties will be able to access a live audio webcast of the session by... Read More

Reports Revenue of $2.4 Billion, Growing 11%, and Net Income of $682 Million, or $1.50 per Diluted Share, Increasing 14% and 16%, Respectively, on a Reported Basis for Third Quarter 2024 Delivers 14% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for Third Quarter 2024 Reports Adjusted Net Income of $716 Million, or Adjusted Diluted EPS of $1.58, for Third Quarter 2024 Raises Full Year 2024... Read More

PARSIPPANY, N.J. / Oct 10, 2024 / Business Wire / The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the fourth quarter of 2024. The dividend will be paid on Tuesday, December 3, 2024, to all holders of record of the Company’s common stock as of the close of business on Thursday, October 31, 2024. About Zoetis As the world’s leading animal health company, Zoetis is driven by a... Read More

PARSIPPANY, N.J. / Sep 26, 2024 / Business Wire / Zoetis and Danone recently announced a joint business development plan to drive sustainable practices on today’s dairy farms through the power of genetics for healthier cows. Combining Danone’s commitment to environmental stewardship with Zoetis’ expertise in animal genetics, the partnership aims to innovate the dairy industry’s approach to breeding for sustainability. The... Read More

PARSIPPANY, N.J. / Sep 19, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Monday, November 4, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live... Read More

PARSIPPANY, N.J. / Aug 20, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 1:05 p.m. ET. Investors and other interested parties will... Read More

Reports Revenue of $2.4 Billion, Growing 8%, and Net Income of $624 Million, or $1.37 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for Second Quarter 2024 Delivers 11% Operational Growth in Revenue and 18% Operational Growth in Adjusted Net Income for Second Quarter 2024 Reports Adjusted Net Income of $711 Million, or Adjusted Diluted EPS of $1.56, for Second Quarter 2024 Raises Full Year 2024... Read More

PARSIPPANY, N.J. / Aug 01, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) today announced that its Board of Directors has approved a multi-year $6 billion share repurchase program as part of its capital allocation plans. The demand for Zoetis’ innovative and market-leading portfolio has enabled the company to execute its disciplined capital allocation strategy by reinvesting in growth opportunities and returning capital to... Read More

PARSIPPANY, N.J. / Jul 30, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will now host its second-quarter 2024 financial results webcast and conference call at 8:00 a.m. (ET) on Tuesday, August 6, 2024, to minimize conflicts with other industry earnings announcements. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . There is no change to... Read More

PARSIPPANY, N.J. / Jul 02, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 6, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live... Read More

Zoetis Foundation provides $3 million grant to the American Red Cross to be utilized over a six-year period to support disaster relief globally Zoetis Inc. launches consumer matching campaign with long-time partner American Humane to support pets impacted by natural disasters across the country PARSIPPANY, N.J. / Jun 26, 2024 / Business Wire / As animals and communities continue to face mounting challenges from natural... Read More

Increased colleague-reported volunteer work by 81% to 16,611 hours Through $8.3 million in grants, the Zoetis Foundation supported 28 initiatives impacting 19 countries to advance opportunities for veterinarians and livestock farmers through education, well-being, and livelihood initiatives Brought to market innovative diagnostics, vaccines and parasiticides to support livestock producers’ animal health and productivity... Read More

PARSIPPANY, N.J. / May 22, 2024 / Business Wire / The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the third quarter of 2024. The dividend will be paid on Wednesday, September 4, 2024, to all holders of record of the Company’s common stock as of the close of business on Thursday, July 18, 2024. About Zoetis As the world’s leading animal health company, Zoetis is driven by a... Read More

PARSIPPANY, N.J. / May 21, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 44 th Annual Growth Stock Conference on Tuesday, June 4, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:40 p.m. CT. Investors and other interested parties will be able to access a live... Read More

PARSIPPANY, N.J. / May 16, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2024 Jaws and Paws Conference on Wednesday, May 29, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 12:05 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting... Read More

Prestigious honor recognizes Zoetis as a leading U.S. company for workplace fairness in talent strategies, workplace and supplier diversity practices and philanthropic engagement Zoetis also recognized on three Fair360 specialty lists, including Top Companies for Women Executives, Top Companies for Latino Executives and Top Companies for Talent Acquisition for Women of Color PARSIPPANY, N.J. / May 14, 2024 / Business Wire /... Read More

Reports Revenue of $2.2 Billion, Growing 10%, and Net Income of $599 Million, or $1.31 per Diluted Share, Increasing 9% and 10%, Respectively, on a Reported Basis for First Quarter 2024 Delivers 12% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for First Quarter 2024 Reports Adjusted Net Income of $634 Million, or Adjusted Diluted EPS of $1.38, for First Quarter 2024 Updates Full Year 2024... Read More

PARSIPPANY, N.J. & TEANECK, N.J. / Apr 28, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation (Nasdaq: PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This... Read More

PARSIPPANY, N.J. / Apr 25, 2024 / Business Wire / As we celebrate World Veterinary Day, the Zoetis Foundation is proud to support veterinarians around the world today and everyday by providing grant support to initiatives promoting veterinary education, mental well-being, and livelihoods. Recognizing the invaluable role veterinarians and veterinary technicians play in advancing animal health, the Foundation is committed to... Read More

Molson Coors’ President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board PARSIPPANY, N.J. / Apr 01, 2024 / Business Wire / Zoetis Inc . (NYSE: ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company... Read More

PARSIPPANY, N.J. / Mar 28, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live... Read More

PARSIPPANY, N.J. / Mar 05, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Barclays Global Healthcare Conference on Thursday, March 14, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 8:30 a.m. ET. Investors and other interested parties will be able to access a live audio webcast... Read More

PARSIPPANY, N.J. / Feb 21, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2024 Animal Health Summit on Thursday, February 29, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 11:40 a.m. ET. Investors and other interested parties will be able to access a... Read More

For Fourth Quarter 2023, Zoetis Reports Revenue of $2.2 Billion, Growing 8%, and Net Income of $525 Million, or $1.14 per Diluted Share, Increasing 14% and 15%, Respectively, on a Reported Basis Delivers 8% Operational Growth in Revenue and 6% Operational Growth in Adjusted Net Income for Fourth Quarter 2023 Reports Adjusted Net Income of $569 Million, or Adjusted Diluted EPS of $1.24, for Fourth Quarter 2023 For Full Year... Read More

PARSIPPANY, N.J. / Feb 06, 2024 / Business Wire / The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the second quarter of 2024. The dividend will be paid on Tuesday, June 4, 2024, to all holders of record of the Company’s common stock as of the close of business on Friday, April 19, 2024. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular... Read More

Prestigious award recognizes the company’s global initiative to advance Diversity, Equity and Inclusion (DE&I) Zoetis is the first animal health company to receive this honor PARSIPPANY, N.J. / Jan 18, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) has been selected as a 2024 Catalyst Award recipient for its global initiative , Awareness and Action Drives Impact , that is advancing equity for women and other underrepresented... Read More

PARSIPPANY, N.J. / Dec 28, 2023 / Business Wire / Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 13, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may... Read More

PARSIPPANY, N.J. / Dec 21, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 3:45 p.m. PT. Investors and other interested parties will be able to access a live audio webcast of the presentation by... Read More

PARSIPPANY, N.J. / Dec 07, 2023 / Business Wire / The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the first quarter of 2024, an increase of 15% from the quarterly dividend rate paid in 2023. The dividend will be paid on Friday, March 1, 2024, to all holders of record of the Company’s common stock as of the close of business on Friday, January 19, 2024. “Zoetis has continued to... Read More

PARSIPPANY, N.J. / Nov 21, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 1:00 p.m. ET. Investors and other interested parties will be able to access a live... Read More

Reports Revenue of $2.2 Billion, Growing 7%, and Net Income of $596 Million, or $1.29 per Diluted Share, Increasing 13% and 14%, Respectively, on a Reported Basis for Third Quarter 2023 Delivers 8% Operational Growth in Revenue and a 13% Operational Growth in Adjusted Net Income for Third Quarter 2023 Reports Adjusted Net Income of $629 Million, or Adjusted Diluted EPS of $1.36, for Third Quarter 2023 Updates Full Year 2023... Read More

PARSIPPANY, N.J. / Oct 12, 2023 / Business Wire / The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.375 per share for the fourth quarter of 2023. The dividend will be paid on Friday, December 1, 2023, to all holders of record of the Company’s common stock as of the close of business on Wednesday, November 1, 2023. About Zoetis As the world’s leading animal health company, Zoetis is driven by a... Read More

Seramount recognized Zoetis for its inclusive benefits for families, including paid gender-neutral parental leave, subsidized childcare, bereavement leave after miscarriage, reimbursement for fertility expenses, increased mental health benefits for colleagues, and a flexible work environment Mary Bradley, Head of Colleague Experience Communications, Named Zoetis’ Working Mother of the Year Dr. Kevin Esch, Executive Director,... Read More

PARSIPPANY, N.J. / Sep 27, 2023 / Business Wire / Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 2, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live... Read More

$2.6 million pledged to six initiatives across Australia, Brazil, the United Kingdom, and the U.S. Commitments made to support veterinary scholarships and debt relief, mental well-being, diversity and inclusion initiatives, and livestock farmers and veterinary livelihoods around the world PARSIPPANY, N.J. / Sep 07, 2023 / Business Wire / Today, the Zoetis Foundation announced that it will distribute $2.6 million during its... Read More

PARSIPPANY, N.J. / Sep 06, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:55 p.m. ET. Investors and other interested parties will be able to access a... Read More

DURHAM, N.C. / Aug 24, 2023 / Business Wire / Zoetis: NEWS FACTS Today, Zoetis, the world leader in Animal Health, marked the official opening of its new building dedicated to diagnostics and biodevices research and development with a ribbon cutting ceremony at its site in Durham, N.C. The ceremony was attended by local... Read More

DURHAM, N.C. / Aug 17, 2023 / Business Wire / Zoetis , the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of a new building dedicated to diagnostics and biodevices research and development (R&D) to meet the needs of veterinarians, livestock farmers and pet owners. The expanded site will serve as the hub for Zoetis’ engineering and... Read More

LINCOLN, Neb. / Aug 09, 2023 / Business Wire / Zoetis: NEWS FACTS Today, Zoetis, the world leader in Animal Health, marked the official opening of its new monoclonal antibodies (mAbs) expansion with a ribbon cutting ceremony at its site in Lincoln, Neb. The ceremony was attended by local officials, including U.S. Senator Pete... Read More

Reports Revenue of $2.2 Billion, Growing 6%, and Net Income of $671 Million, or $1.45 per Diluted Share, Increasing 27% and 29%, Respectively, on a Reported Basis for Second Quarter 2023 Delivers 9% Operational Growth in Revenue and a 12% Operational Growth in Adjusted Net Income for Second Quarter 2023 Reports Adjusted Net Income of $652 Million, or Adjusted Diluted EPS of $1.41, for Second Quarter 2023 Updates Full Year... Read More

LINCOLN, Neb. / Aug 04, 2023 / Business Wire / Zoetis , the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of our new monoclonal antibodies (mAbs) expansion, which will enable the site to increase production of products that control osteoarthritis pain in dogs and cats – our largest growing area of need for pet care customers. The... Read More

PARSIPPANY, N.J. / Jul 12, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) has been named to Fast Company’s list of Best Workplaces for Innovators for 2023 . Zoetis is the only stand-alone animal health company to be included on this year’s list which honors businesses that demonstrate a commitment to encouraging innovation at all levels. “Our innovative culture means we are always seeking to understand how we can meet our... Read More

PARSIPPANY, N.J. / Jul 10, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) today announced the addition of Ester Banque as Executive Vice President and President, U.S. Operations, for the company, effective July 10, 2023. Ms. Banque is an accomplished global senior executive with over 30 years of experience in health sciences... Read More

PARSIPPANY, N.J. / Jun 30, 2023 / Business Wire / Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 8, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live... Read More

$7.4 million in corporate giving invested in communities, and an additional $5.7 million distributed through Zoetis Foundation grants to support veterinarians and farmers Continued progress toward colleague diversity aspirations, including increased representation of women at the director level and above globally from 32% in 2020 to 37% in 2022, aspiring to reach 40% by 2025 Received approval for several livestock vaccines... Read More

PARSIPPANY, N.J. / May 30, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2023 Jaws and Paws Conference on Wednesday, May 31, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 3:35 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of... Read More

PARSIPPANY, N.J. / May 25, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) is hosting an investor day at 9:00 a.m. ET today at the New York Stock Exchange, where the company will dive into its compelling growth ambitions, its innovative and robust R&D pipeline and its financial roadmap to continue delivering shareholder value, as it Shapes Animal Health for the Next Decade . During today’s presentations, Chief Executive... Read More

PARSIPPANY, N.J. / May 11, 2023 / Business Wire / The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.375 per share for the third quarter of 2023. The dividend will be paid on Friday, September 1, 2023, to all holders of record of the Company’s common stock as of the close of business on Friday, July 21, 2023. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular... Read More

Librela™ is the first and only injectable monoclonal antibody (mAb) treatment for the control of canine OA pain approved in the United States Zoetis continues to advance innovation with a new era of pain management for dogs PARSIPPANY, N.J. / May 05, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of... Read More

Reports Revenue of $2.0 Billion, Growing 1%, and Net Income of $552 Million, or $1.19 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for First Quarter 2023 Delivers 4% Operational Growth in Revenue and a 3% Operational Decline in Adjusted Net Income for First Quarter 2023 Reports Adjusted Net Income of $607 Million, or Adjusted Diluted EPS of $1.31, for First Quarter 2023 Maintains Full Year 2023... Read More

PARSIPPANY, N.J. / May 01, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) will host an Investor Day on Thursday, May 25, 2023, at the New York Stock Exchange featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Chief Financial Officer; Robert Polzer, Ph.D., President of Research and Development; and other members of the Zoetis executive team. Zoetis will provide an update on the company’s strategy to deliver... Read More

$5.3 million pledged to 21 initiatives across Africa, Brazil, China, U.S. and for those impacted by the earthquake in Türkiye Commitments made to support veterinary scholarships, diversity and inclusion programming, mental well-being, livestock farmers and veterinary livelihoods around the world PARSIPPANY, N.J. / Apr 05, 2023 / Business Wire / Today, the Zoetis Foundation announced that it will distribute $5.3 million... Read More

PARSIPPANY, N.J. / Mar 30, 2023 / Business Wire / Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 4, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live... Read More

PARSIPPANY, N.J. / Mar 13, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) has been recognized by Ethisphere, a global leader in defining and advancing the standards of ethical business practices, as one of the 2023 World’s Most Ethical Companies . In 2023, 135 honorees were recognized, spanning 19 countries and 46 industries. Zoetis is one of three pharmaceutical companies and the only standalone animal health company... Read More

PARSIPPANY, N.J. / Mar 03, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the TD Cowen Health Care Conference on Monday, March 6, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 11:10 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the... Read More

PARSIPPANY, N.J. / Mar 01, 2023 / Business Wire / Zoetis is pleased to receive a $15.3 million grant from the Bill & Melinda Gates Foundation to further develop and integrate innovative solutions to advance veterinary care and diagnostic services that will ultimately improve livestock health and productivity in Sub-Saharan Africa. The grant will help Zoetis to expand its original African Livestock Productivity and Health... Read More

PARSIPPANY, N.J. / Feb 28, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2023 Animal Health Summit on Thursday, March 2, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:30 p.m. ET. Investors and other interested parties will be able to access a live... Read More

PARSIPPANY, N.J. / Feb 14, 2023 / Business Wire / Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2022 and provided full year guidance for 2023. The company reported revenue of $2.0 billion for the fourth quarter of 2022, which was an increase of 4% compared with the fourth quarter of 2021. On an operational 1 basis, revenue for the fourth quarter of 2022 increased 9% compared... Read More

PARSIPPANY, N.J. / Feb 08, 2023 / Business Wire / The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.375 per share for the second quarter of 2023. The dividend will be paid on Thursday, June 1, 2023, to all holders of record of the Company’s common stock as of the close of business on Friday, April 21, 2023. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular... Read More

Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 14, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2022 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis... Read More

Zoetis Inc. (NYSE:ZTS) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 1:30 p.m. PT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting... Read More